Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 116.50 115.00 118.00 116.50 116.50 116.50 55,528 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.1 -13.9 -35.9 - 66

Reneuron Share Discussion Threads

Showing 8301 to 8323 of 8325 messages
Chat Pages: 333  332  331  330  329  328  327  326  325  324  323  322  Older
DateSubjectAuthorDiscuss
11/6/2021
13:42
Next stop 150?
small crow
11/6/2021
06:59
Whats the time frame on that TP. 10yrs?
ps0u3165
10/6/2021
10:30
I'm starting to think Rene, with all its potential, needs to change the top team. The stroke trial in USA, no jv partner to takeover the trial, hrpc delay - show to me a weakness in delivery
stutes
10/6/2021
08:58
FWIW: '@Stifel maintain their BUY recommendation for @ReNeuronPLC following the retinal Phase II trial announcement - "...any significant stock weakness on this news (now c.-11% to 109p vs. FTSE AIM All share 0%) is overdone..." Target price 400p https://twitter.com/WalbrookPR/status/1402669241921376261
zho
09/6/2021
14:58
Nice 10% made and banked. Who were the suckers that sold out?
bantam175
09/6/2021
14:14
I have also picked up some more. Bacterial infection is a common risk with surgery. I think this is the first one they have reported in their trials. There is a delay of 3 months but the treatment is impressive on the 12 months results and I see no reason for those not to be matched or improved upon for the current patients. For me this is a long hold and 3 months will make no difference. I hope the patient recovers quickly.
pdt
09/6/2021
13:52
MM's churn 'earning' their Pol Roger today....
small crow
09/6/2021
13:21
https://mobile.twitter.com/BabblerBestBets/status/1402601215079419914
babbler
09/6/2021
13:21
I topped up too. If it was bad hygiene around one patient I don't think 25 percent off the company value is appropriate. Dyor
cottonpickers
09/6/2021
13:19
Agree - topped up. In for the medium to long-term so this is an opportunity. It will soon regain former upward trajectory to turn these 95p purchases into 150p IMO
small crow
09/6/2021
13:11
Fill yer boots. Won't be down here long. All imho dyor etc etc
bantam175
09/6/2021
13:03
Or they find the source of the infection fairly quickly and move on.
babbler
09/6/2021
13:02
The implications of the delay are that they will miss the conference season this year to announce clinical data. It will also mean that they won't have 12 months data until the end of 2022. All this pushes back a potential phase 3 pivotal trial to 2023/24 with the possibility of market approval in 2025/26.
whatno
09/6/2021
12:49
Ridiculous overreaction. Bacterial infection is not down to the therapy. Infection risk is always present in such procedures. Not ideal but not worthy of a 25% pullback!
rrb
09/6/2021
12:40
Today's news hrpc trial infection is another piece of misfortune for Rene. I think it's time for Rene to sell itself
stutes
09/6/2021
12:37
Let's hope there's no lasting damage. I don't believe RENE has permission from the regulators for redosing so this patient can't have a repeat.
whatno
09/6/2021
12:35
Massive overreaction on a generally down-day for everything, I suspect someone wants to get in cheap and has instructed accordingly - large (huge?) buys expected to show up over next few days IMO. This random unfortunate event has been a gift to them.
small crow
09/6/2021
12:20
The trials have been going on for quite some time yes? This is the first problem like this as far as I am aware. There will be many likely causes to an infection in any surgery. Let's hope they can pin down exactly what caused it. It sounds like the patient (poor sod - best wishes to him/her) seems to be responding well. It will be interesting to see what happens to their eyesight once the infection is dealt with.
bradders51
09/6/2021
12:16
It's very unfortunate. I guess they need to know whether the batch was contaminated or whether the infection was introduced during the procedure itself. There's also a question of what damage the infection may have done to the transplanted cells of the unfortunate patient being treated.
whatno
09/6/2021
12:06
starting to lose my patience with this lot, not only ridiculous amount of time to get to mkt but stuff like this. yes i know it happens but they still remind me of bunch of people doing a science project with our money with no commercial outlook at all
martinfrench
09/6/2021
12:04
Not exactly ideal! ""Released 11:55:07 09 June 2021 RNS Number : 3482B ReNeuron Group plc 09 June 2021 ReNeuron Group plc ("ReNeuron" or the "Company") Update for hRPC therapy candidate study ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides an update on the Company's Phase 2a clinical evaluations for the treatment of retinitis pigmentosa ('RP'), an inherited, degenerative eye disease. Further to the update on 15 January 2021, the Company has activated sites in Spain and the UK, to expand the Phase 2a extension study outside the US, thus representing a total of four actively enrolling sites worldwide. The most recently enrolled subject was treated last week, undergoing a successful surgical procedure to implant the hRPC drug product. Five days following treatment, the subject presented with a presumed bacterial intraocular infection in the treated eye which impacted their vision, and was treated initially with an appropriate regimen of antibiotics, to which they responded with clinical improvement. Systemic anti-inflammatory therapy was subsequently added, and the subject continues to improve on this regimen. The origin of the presumed infection is not yet clear. As a precaution, dosing of further subjects in the study has been temporarily suspended while an investigation into the cause of the event continues. This is likely to lead to a delay to the study, and the Company now expects three-month data from the extension segment of the Phase 2a study to be available in Q4, rather than Q3, of this year. The Company will provide a further update in due course.""
goyathlay
08/6/2021
14:30
The clinicaltrials.gov website is still showing Oxford eye hospital as "not yet recruiting". I can only assume this is due to the huge backlog of NHS work that needs to be cleared before staff can work on research projects. Unless the situation improves soon, RENE will need to make some hard choices regarding Professor Maclaren's involvement unless they opt for a delay until next year.
whatno
08/6/2021
13:34
Thanks. Interesting. I know the company needs to tell a bullish story, but looking at valuations, capabilities and 'Done deals', its very easy to get into the mindset of Rene being valued at a fraction of its potential worth - even if only the hRPC proves partial efficacy. I'd love a crystal ball!
bg23
Chat Pages: 333  332  331  330  329  328  327  326  325  324  323  322  Older
ADVFN Advertorial
Your Recent History
LSE
RENE
Reneuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210614 08:50:06